Marken has been granted a 12-year license to ship biological samples and drug product within China. The company has also grown its presence in China, adding staff trained and certified on IATA regulations and anti-corruption policies. Marken has also initiated its Phase II depot roll out plan with the construction of its pharmaceutical depot near the Beijing International airport.
 
Wes Wheeler, chief executive officer of Marken, said, “We recognize the value of the clinical trial market in Asia and what economic impact the region has for many of our pharmaceutical clients. China, Korea and Japan are now clearly in focus for Marken and we will continue to analyze and anticipate new opportunities, both within China as well as other parts of Asia and the world as a whole.”